Stay updated with breaking news from Vas Narasimhan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Discover Novartis' Q1 EPS soars 17% to $1.80, surpassing estimates. Sales hit $11.83B, up 10%. Entresto sales surge 36%, Cosentyx up 25%. CEO Vas Narasimhan bullish on mid & long-term growth.
Jammu Tawi: Around 200 delegates comprising both international delegates and Indian companies were taken in for a guided tour of the Genome Valley in Hyderabad in two groups on the inaugural day of BioAsia 2024. The groups toured around IKP Knowledge Park (incubation centre) and. Multitalented Facility Neovantage (Takshashila) to understand the facility and possible
Swiss drugmaker Novartis reported a 6% gain in fourth-quarter adjusted net income on Wednesday, helped by cost cuts and strong growth of recently launched drugs. Core net income for the quarter came in at $3.13 billion, it said in a statement, missing analysts' estimate of about $3.3 billion, as per LSEG data. Novartis also extended its mid-term guidance, saying it expected sales to grow 5% per year until 2028, when adjusting for currency swings.
Swiss pharma major Novartis on Wednesday updated its mid-term guidance as it reported a fourth-quarter net income of $8.48 billion, up from last year's $1.47 billion. Earnings per share were $4.14, significantly higher than $0.69 a year ago. Looking ahead for fiscal 2024, the company projects net sales to grow mid single digit and core operating income to grow high single digit. Further, the company updated mid-term guidance, with net sales expecting to grow 5% cc CAGR 2023-2028 with core operat
NVS earnings call for the period ending December 31, 2023.